Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

Published Date: 03 Jun 2025

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment

2.

Cancer patients rarely use ancestry testing.

3.

Best foot forward—chemo care should include podiatry, say researchers

4.

Is Vitamin D a Key to Better Breast Cancer Survival?

5.

Low Income, Education Tied to Depression in Older Adults


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot